January 5, 2022
Life Sciences
  • COVID-19 vaccine partners Pfizer and BioNTech SE are working together to develop an mRNA vaccine for shingles. BioNTech is contributing its proprietary mRNA technology while Pfizer is offering its antigen research. The drugmakers hope their shingles shot will be easier to ramp up than the highly effective protein-based vaccine from GlaxoSmithKline PLC, which was approved in 2017. (Articles here and here)